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Thymoma and its recurrence patterns have been the subject of lively discussion over the past 20 years, and many studies have been published1–4 that have provided conflicting 
results. Doubt exists as to whether surgery (including redo) is better than chemotherapy, 
radiation, and chemoradiation approaches. At a glance, all reported studies suffer from 
the same significant bias, namely, the absence of data obtained through randomized tri-
als. Criteria are consistently and clearly reported for surgery (and redo), e.g., the tumor 
is resectable, and the patient is fit to undergo even an extended operation, but subse-
quent management has no basis other than scientific supposition; the indication for redo- 
surgery is not evidence based. However, as underlined by a recent survey conducted by the 
European Society of Thoracic Surgeons,5 there is general consensus that recurrent neo-
plasms that are resectable should be removed. Some, including our group, have reported 
repeated operations.6–8
In this setting, the study by Bae et al.,9 which analyzed the 23-year outcome of 411 
patients with thymoma at a single institution, adds very interesting information to the 
debate. Their results have great potential impact on the clinical decision-making process. 
Focusing on treatment of recurrent disease (41 patients: 15 surgical and 26 nonsurgical), 
these investigators comprehensively analyzed the correlations among clinical, surgical, and 
pathological factors and long-term outcomes. They confirmed that thymoma is indolent 
and slow growing with a limited recurrence rate of 14%, a recurrence time-span often 
lasting decades, and a very long mean disease-free survival interval of 52 months (range, 
6–234 months). The resilience of thymoma makes it an insidious entity. In addition to being 
retrospective and based on a single center’s experience, Bae’s study was limited by the long 
duration of the recruitment and the relatively small population (outstanding in absolute 
terms). Granting these limitations, the study supported surgical treatment for recurrent thy-
moma, which is crucial. Bae et al.9 found that patients in whom a complete reresection after 
recurrence was achieved had a 10-year survival rate of 91.7%, which was comparable with 
those who did not have recurrence c(86.5%) and dramatically better when compared with 
those who were not reresected or those in whom the reresection was incomplete (56.7%).
Therefore, it can be inferred that the only determinant of prognosis is completeness 
of the resection. Moreover, attention must be paid to complete resection, even in cases in 
which recurrences occur, and this must be indicated in every case in which the complete-
ness can be anticipated and the patient’s condition is good enough to undergo another 
surgery.7,8 In this scenario, chemotherapy and radiation therapy and their combination are 
confined to very limited cases.
The study by Bae et al.9 added useful information when the standard definitions of 
thymoma recurrence are challenged with related clinical evidence. In fact, very recently, 
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the International Thymic Malignancy Interest Group defined 
a standard set of definitions for recurrence, which was classi-
fied as local (anterior mediastinum), regional (intrathoracic, 
not contiguous with the thymus), and distant (intrapulmonary 
and extrathoracic).10 The Bae et al. study9 confirmed that if 
data are analyzed according to this classification, patients with 
local recurrence have a better survival rate than those with 
regional or distant recurrence.
Importantly, the fact that the number of recurrent lesions 
could represent a significant determinant of (worse) prognosis 
after surgery is advocated by other authors.11,12 These findings 
are indeed interesting, and they pave the way for further and 
deeper discussion on (1) the correlation between the site of 
recurrence and treatment and (2) the correlation between the 
number of localizations of the disease and the completeness 
of surgery.
In both scenarios, we could easily reduce the burden of 
decision making by focusing on the evidence showing that the 
completeness of resection is the only real point of interest. The 
matter of local/regional versus distant disease occurrence (and 
recurrence) has a direct impact on the decision-making pro-
cess as to whether surgery is indicated. Thymoma is relatively 
free from oncological complexity (as found, for example, in 
the case of lung cancer, where resectability and operability 
are determined on a stage-by-stage basis), because the antici-
pation of reasonable completeness is the only parameter sub-
stantially influencing the decision as to whether to operate. 
Furthermore, in considering the number of localizations, we 
go back again to the question of anticipated completeness of 
resection. Some authors have focused on the issue at stake 
here, using multiple pleural recurrences as the easiest model 
for this discussion: “In case of single or few pleural implants 
the surgical resection is quite simple and the resection can 
be also judged ‘radical’; on the other hand a massive pleu-
ral recurrence and the involvement of major structures could 
require extensive resections and in this case the radicality 
becomes questionable…”12
In conclusion, we affirm, as largely supported by Bae’s 
experience,9 that in the case of thymoma and recurrent thy-
moma, the completeness of resection is the strongest deter-
minant of long-term survival irrespective of other prognostic 
factors. Indeed, considering the absolute and relative weight 
or other factors, such as the pattern of diffusion and the num-
ber of recurrent lesions or other parameters, matched against 
the completeness of resection as prognostic determinants, we 
agree with Ruffini et al.13 in advocating for further large scale, 
possibly multicenter investigations.
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